体外诊断(IVD)的全球市场:趋势与市场最新资讯:2025年

In Vitro Diagnostic (IVD) Trends and Market Update, 2025

出版日期: 2025年04月08日 | 出版商:

Kalorama Information | 英文 50 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

本报告提供了在持续的经济和全球不确定性背景下动态体外诊断（IVD）市场的最新见解。

2024 年，IVD 市场将继续扩大，儘管 COVID-19 检测收入有所下降，但大多数细分市场仍将实现成长。人工智慧驱动的创新、监管变化和全球医疗保健支出的变化正在塑造竞争格局，并使 IVD 行业更具弹性。

产业重点关注且有望在未来 IVD 领域发挥关键作用的关键成长领域包括：

照护现场糖尿病检验
伴随式诊断技术
免疫化学
质谱分析

核酸化验
遗传基因检验
HPV分子诊断

本报告提供全球体外诊断(IVD)市场相关调查，彙整推动市场要素主要的与产业趋势，IVD革新形成的新产品开发，竞争情形的考察主要企业趋势，新的成长机会及策略性成长领域等资料。

Kalorama Information's "In Vitro Diagnostic (IVD) Trends and Market Update, 2025" provides the latest insights into the dynamic IVD market amid ongoing economic and global uncertainties. Published twice a year-first in April 2025 and again in Q4 2025, following the release of Kalorama's annual 1,600-page study, "The Worldwide Market for In Vitro Diagnostics (IVD), 18th Edition"-this report serves both as a standalone resource and a companion to Kalorama's annual flagship IVD analysis.

In 2024, the IVD market continued to expand, with most segments experiencing growth, despite the decline in COVID-19 testing revenues. AI-driven innovations, regulatory shifts, and changes in global healthcare spending are shaping the competitive landscape, reinforcing the resilience of the IVD sector.

Key growth areas attracting industry attention and that are anticipated to play a significant role in the future of IVD include:

Point-of-care diabetes testing
Companion diagnostics technologies
Immunochemistry
Mass spectrometry

Nucleic acid assays
Gene testing
HPV molecular diagnostics

This report delivers timely and actionable intelligence, covering:

Market drivers and major industry trends
New product developments shaping IVD innovation
Competitive landscape insights and activities of key players
Emerging opportunities and strategic growth areas

With a commitment to delivering precise and up-to-date market intelligence, Kalorama Information continues to provide industry stakeholders with critical data and expert analysis to navigate the ever-evolving IVD landscape.

Chapter 1: Worldwide IVD Market Update - April 2025

IVD Market Demand and Growth
- Figure 1-1: Segment Performance Commentary, Q1-Q4 2024
- Table 1-1: Global In Vitro Diagnostic Sales, by Product Market, 2024 ($ million) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
- Figure 1-2: Quarterly IVD Segment Performance, by Segment, Q1 2024 - Q4 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
- Figure 1-3: IVD Segment Performance, Total Market Value, 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
COVID-19 Diagnostic Markets
- Table 1-2: COVID-19 Product Sales, 2024 ($ million) [Immunoassay (Antigen, Serology), Molecular, Rapid]
Effect of COVID-19 on Market Segments
- Table 1-3: IVD Market Excluding and with COVID-19, 2024 ($ million)
- Figure 1-4: IVD Market Distribution, by Segment, 2024 (%) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
- Figure 1-5: IVD Market by COVID-19 and non-COVID Markets, Quarterly Performance, 2024 ($ million) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
- Table 1-4: Global In Vitro Diagnostic Market, YoY Growth 2023-2024 (%) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
- Figure 1-6: Global In Vitro Diagnostic Market - YoY Growth 2023-2024 (%) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]

Chapter 2: Product Trends and New Developments

Liquid Biopsy
Mass Spectrometry
Immunoassay
Molecular
Personalized Medicine
POC
Sequencing
Antigen/Antibody
Molecular

Chapter 3: Top IVD Market Participant Results

Selected Competitive Leader Updates
- Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2023-2024 (%) [Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific]
- Figure 3-2: IVD Sales Changes in Market Distribution, 2021-2024 - Roche and Abbott Battle for #1 Spot (%) [Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, Exact Sciences, Hologic, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werfen, Others]
- Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2022-2024 ($ million)
Q4 2024, Q1 2025 M&A Activity
- Table 3-1: Q4 2024, Q1 2025 Merger and Acquisition Activity
Abbott Laboratories
- Table 3-2: Abbott Corporate Summary
Becton Dickinson and Co
- Table 3-3: Becton Dickinson Corporate Summary
bioMerieux SA
- Table 3-4: bioMerieux Corporate Summary
Danaher Corporation
- Table 3-5: Danaher Corporation Summary
Dexcom, Inc
- Table 3-6: Dexcom Corporate Summary
Exact Sciences
- Table 3-7: Exact Sciences Corporate Summary
QuidelOrtho Corporation
- Table 3-8: QuidelOrtho Corporate Summary
Roche Diagnostic
- Table 3-9: Roche Diagnostic Corporate Summary
Siemens Healthineers
- Table 3-10: Siemens Healthineers Corporate Summary
Sysmex Corporation
- Table 3-11: Sysmex Corporate Summary
Thermo Fisher Scientific
- Table 3-12: Thermo Fisher Scientific Corporate Summary